Lophora’s rich and easily expandable pipeline can address multiple psychiatric disorders.

Like other agonists of the 5-HT2A receptor, LPH-5 is believed to be a potent psychoplastogen and has shown anti-depressant effect in an animal model of depression at doses that do not induce hallucinogenic effects, indicating that this compound could be used for micro or macro-dosing paradigms to address a breadth of CNS-related indications, which do or do not require induction of the psychedelic state